FRS2 and small cell lung carcinoma: In small cell lung cancer (SCLC), FGFR inhibitors demonstrated delayed progression in both in vivo and in vitro experiments by inhibiting downstream MAPK and PI3K-Akt signaling pathways through the inhibition of FRS2 phosphorylation 24.